Bio-Bridge Science Selected to Participate in Prestigious Study Targeting Health Care Solutions in Emerging Countries.OAK BROOK, Ill. -- Bio-Bridge Science, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :BGES BGES Belgian Group for Endoscopic Surgery ) announced today its participation in a study, entitled Private Sector Development in Developing Countries: Targeting Local Health Needs through Health Technology, which explores how small to medium enterprises can address local health needs in Innovating Developing Countries (IDCs) such as China, India, Brazil and South Africa. Two members of the research team, Dr. Sarah E. Frew and Dr. Peter A. Singer, visited Bio-Bridge Science's soon to be finished GMP GMP (guanosine monophosphate): see guanine. lab facility and met with senior management on May 15, 2006 in Beijing. As part of the study, Bio-Bridge Science, Inc. will participate in exploring ways that the domestic private sector can contribute to the development of health technologies targeted to address local health needs. The mission of Bio-Bridge Science, Inc. is to develop and produce new vaccines and drugs to treat human diseases and improve human health. "We are honored to be selected to participate in this study," said Dr. Liang Qiao, Chief Executive Officer of Bio-Bridge. "The exposure among many of the key thought and opinion leaders in these countries will raise our profile in these key markets. As a Company that has focused on developing cost-effective vaccines for large unmet medical needs in countries such as China, we believe that we are uniquely qualified to offer solutions to these challenges." About Bio-Bridge Science: Bio-Bridge Science is a biotechnology firm focused on the development of vaccines with broad therapeutic and preventive applications. Through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. in Beijing, Bio-Bridge is developing a promising new HIV Vaccine HIV vaccine AIDS As of mid-2005, there is no viable anti-HIV vaccine. See AIDS. that is expected to enter clinical trials this year in China. The vaccine, based on exclusive technology co-developed by CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. Liang Qiao, an associate professor at Loyola University Chicago's Strich School of Medicine, targets infection in mucosal tissues, the first type of tissue attacked by HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. . The Chinese government, mindful of the rapid expansion of AIDS in China has, through the "Green Mile Policy", acted to expedite the approval of domestically produced HIV Vaccines and has dramatically increased its spending on AIDS-related research. In accordance with this policy, Bio-Bridge expects to bring its therapeutic HIV Vaccine A therapeutic HIV vaccine is a vaccine that when used provides immunity to HIV and the resultant AIDS condition. An effective HIV vaccine has been sought in medical research since the mid-1980s, although progress has been made only relatively recently. to market as early as late 2008, far in advance of many other HIV Vaccines currently in development. Bio-Bridge is currently constructing a new $3 million state-of-the-art GMP research and manufacturing facility in Beijing, which is expected to be completed by mid-year. The facility will also be used to develop vaccines against cervical cancer and colon cancer under the same technology platform as the HIV vaccine. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion